ASX announcements


 
    Change of Director's Interest Notice  
 
    Market Update  
 
    Appendix 4D and Half Year Accounts  
 
    Appendix 4C - quarterly  
 
    Final Director's Interest Notice  
 
    Director Resignation  
 
    Change of Directors Interest Notice X 5  
 
    Appendix 3B  
 
    Results of Meeting  
 
    Quarterly Activities Report  
 
    Appendix 4C - quarterly  
 
    Notice of Annual General Meeting/Proxy Form  
 
    Annual Report to shareholders  
 
    Appendix 4G and Corporate Governance Statement  
 
    Bioxyne Expands to Indonesia with Acquisition  
 
    Quarterly Activities and Quarterly Cash Flow Report  
 
    Change of Director's Interest Notice  
 
    Change of Director's Interest Notice  
 
    Bioxyne to Distribute GRAYNS Starch Reducing Rice Cooker  
 
    Clarification to Announcement  
 
    Expands to Thailand, Philippines, Myanmar, Cambodia,  
 
    Appointment of Non-Executive Director  
 
    Securities Trading Policy - Updated  
 
    Quarterly Activities and Quarterly Cash Flow Reports  
 
    Investor Update  
 
    Appendix 4D and Interim Financial Report  
 
    Unique NZ Colostrum Honey Dairy Product for China and S.E.A  
 
    Director Resignation  
 
    Quarterly Activities and Quarterly Cash Flow Report Dec 17  
 
    Change of Director's Interest Notice  
 
    Additional New Products Launched for Direct Sales  
 
    Appendix 3B  
 
    Third Party Claim  
 
    Appendix 3B  
 
    Change of Directors Interest X 3  
 
    Positive Bioxyne Gut Health Clinical Trial Results  
 
    Change of Directors Interest Notice X 2  
 
    Bioxyne Launches NZ Dairy Formula Product in South East Asia  
 
    Appendix 3B Amended  
 
    Appendix 3B  
 
    Change of Share Registry  
 
    Results of Meeting  
 
    Letter to Optionholders  
 
    Change of Director's Interest Notice  
 
    Appendix 3B  
 
    Notice of Annual General Meeting/Proxy Form  
 
    Quarterly Activities Report and Appendix 4C  
 
    Malaysian Direct Selling Licence to Propel Bioxyne into MLM  
 
    Appendix 3B  
 
    Response to ASX Price Query Letter  
 
    Appendix 3B  
 
    Appendix 4G  
 
    Annual Report to shareholders  
 
    Appendix 3B  
 
    BXN Extends Product Range, New Website, Marketing Campaign  
 
    Appendix 4E Preliminary Final Report  
 
    Change in substantial holding  
 
    Directors Change in Interest X 3  
 
    Appendix 3B  
 
    Results of Meeting  
 
    Quarterly Activities Appendix 4C  
 
    Appendix 3B  
 
    Notice of General Meeting/Proxy Form  
 
    Change in substantial holding  
 
    Directors Initial Interest Notice X 2  
 
    Becoming a substantial holder  
 
    Appointment of Directors  
 
    Share Sale Facility for Unmarketable Parcels  
 
    Directors Change in Interest X 2  
 
    Appendix 3B  
 
    Rights Issue - Notification of Shortfall  
 
    Appendix 3B  
 
    Rights Issue - Letter to Ineligible Shareholders  
 
    Letter to Shareholders - Rights Issue  
 
    Prospectus - Rights Issue  
 
    Quarterly Activities and Cash Flow Report March 2017  
 
    Cleansing Statement  
 
    Appendix 3B  
 
    Letter to Optionholders  
 
    Listing Rule 7.1A Information  
 
    Appendix 3B  
 
    Acquires NZ Product Company for Direct Sales Asia Pacific  
 
    Trading Halt  
 
    Appendix 4D and Half Year Report  
 
    Bioxyne to Access Chinese Market for Online Sales via JD.com  
 
    Response to ASX Appendix 3Y Letter  
 
    Issue of Options, Appendix 3B, Appendix 3Y X 2  
 
    Quarterly Activities and Cash Flow Report Dec 2016  
 
    Change of Director's Interest Notice  
 
    Details of Company Address  
 
    Results of Meeting  
 
    AGM Notice - Amendment to Resolutions  
 
    AGM - Amendment to Resolutions  
 
    Final Director's Interest Notice  
 
    Director Resignation  
 
    Launch of Two Products Containing PCC Onto Australian Market  
 
    Quarterly Activities Report and Appendix 4C  
 
    Notice of Annual General Meeting/Proxy Form  
 
    Recruitment for Clinical Trial of Proprietary Probiotic PCC  
 
    Annual Report to shareholders  
 
    Appendix 4G and Corporate Governance Statement  
 
    Becoming a substantial holder  
 
    Ceasing to be a substantial holder  
 
    Management Restructure  
 
    Company Secretary Appointment/Details of Company Address  
 
    Appendix 4E - Preliminary Final Report  
 
    Appendix 4C - June Quarterly  
 
    Bioxyne Commences New Clinical Trial  
 
    Directors Equity Based Incentives  
 
    Board Exercises Options  
 
    Appendix 3B - Exercise of Directors' Options  
 
    Change of Director's Interest Notice - Patrick Ford  
 
    Change of Director's Interest Notice - Anthony Ho  
 
    Change of Director's Interest Notice - George Cameron-Dow  
 
    Appendix 4C - March quarterly  
 
    Bioxyne Announces 2016 Goals  
 
    Bioxyne Investor Presentation  
 
    Change of Director's Interest Notice - A Ho  
 
    Appendix 4D - Half Yearly Report and Accounts  
 
    Initial Director's Interest Notice - Dr Peter French  
 
    Appointment of Executive Director Dr Peter French  
 
    Tony Ho - Change of Director's Interest Notice  
 
    Appendix 4C - December Quarterly  
 
    Results of Annual General Meeting  
 
    Mariposa Health Inc. Investment Update  
 
    Change of Director's Interest Notice - Patrick Ford  
 
    Appendix 4C - September Quarterly  
 
    2015 Notice of Annual General Meeting and Proxy Form  
 
    Appendix 4G  
 
    2015 Annual Report to Shareholders  
 
    Appendix 4E - Preliminary Final Report  
 
    2015 Financial Year Profit Update  
 
    Appendix 4C - June Quarterly  
 
    Becoming a Substantial Holder - Ondek Pty Ltd  
 
    Change of Director's Interest Notice - George Cameron-Dow  
 
    Ceasing to be a substantial holder - Fleming  
 
    Appendix 4C - March Quarterly  
 
    Change of Director's Interest Notice - George Cameron-Dow  
 
    Appendix 4D - Half Yearly Report and Accounts  
 
    Change of Director's Interest Notice - P Ford  
 
    Change of Director's Interest Notice - A Ho  
 
    Appendix 4C - December Quarterly  
 
    Change of Director's Interest Notice - A Ho  
 
    Change of Director's Interest Notice - P Ford  
 
    Change of Director's Interest Notice - G Cameron-Dow  
 
    Appendix 3B - Issue of Employee Options  
 
    Change of Registered Office  
 
    Results of 2014 Annual General Meeting  
 
    Change of Director's Interest Notice - P Ford  
 
    Change of Director's Interest Notice - A Ho  
 
    Notice of 2014 Annual General Meeting/Proxy Form  
 
    Appendix 4C - September Quarterly  
 
    Annual Report to Shareholders  
 
    Appointment of Strategic Marketing Consultant  
 
    Appendix 4E - Preliminary Final Report  
 
    Top 20 securityholders  
 
    Appendix 4C - June Quarterly  
 
    Initial Director's Interest Notice - George Cameron-Dow  
 
    Final Director's Interest Notice - Jeremy Curnock-Cook  
 
    Resignation and Appointment of Directors  
 
    Change of Director's Interest Notice - Jeremy Curnock-Cook  
 
    Ceasing to be substantial holder - Phillip Asset Management  
 
    Becoming a substantial holder - Fleming SG Capital SO  
 
    Options Expiry  
 
    Appendix 4C - March Quarterly  
 
    Appendix 3B - Quotation Following ASX Escrow Release  
 
    Change of Director's Interest Notice - P Ford  
 
    Release of Shares from Escrow  
 
    Half Yearly Report and Accounts  
 
    Change of Director's Interest Notice - P Ford  
 
    Completion of the Sale of HI-164 Program  
 
    Change of Director's Interest Notice - P Ford  
 
    Change in substantial holding  
 
    Appendix 4C - December Quarterly  
 
    Amended Change of Director's Interest Notices  
 
    Change of Director's Interest Notice - P Ford  
 
    Change of Director's Interest Notice - J C Cook  
 
    Change of Director's Interest Notice - A P Ho  
 
    Appendix 3B - EGM Approved Share and Option Issues  
 
    Results of EGM  
 
    Expiry of Unquoted Options  
 
    Bioxyne Limited CEO Steps Down  
 
    Sale of HI-164OV Hunter Immunology Pty Ltd  
 
    Results of 2013 AGM  
 
    Notice of Extraordinary General Meeting/Proxy Form  
 
    Response to ASX query  
 
    Appendix 4C - September Quarterly  
 
    Notice of Annual General Meeting/Proxy Form  
 
    30 June 2013 Full Year Statutory Accounts  
 
    Appendix 4E - Preliminary Final Report  
 
    Response to ASX query  
 
    Appendix 4C - June Quarterly  
 
    Company Secretary Resignation  
 
    Termination of proposed acquisition - Vitality Devices  
 
    Appendix 4C - quarterly - 31 March 2013  
 
    Appendix 3B - Quotation of Escrowed Stock  
 
    Release of Shares from Escrow  
 
    Appendix 3B and s708A(6) Notice - Completion of Placement  
 
    Vitality Devices Acquisition Update  
 
    Half Yearly Report and Accounts to 31 December 2012  
 
    Completion of placement follow up  
 
    Reinstatement to Official Quotation  
 
    Completion of Placement  
 
    Suspension Request  
 
    Suspension from Official Quotation  
 
    Appointment of new CFO and change of registered office  
 
    Trading Halt  
 
    Proposed Acquisition of Vitality  
 
    Status Review HI 164OV Further Update  
 
    Appoints New Company Secretary  
 
    Response to ASX query  
 
    Appendix 4C - quarterly  
 
    Change of Director's Interest Notice  
 
    Update and Status review of HI-164 therapy for COPD  
 
    Change of Director's Interest Notice  
 
    Final Director's Interest Notice  
 
    Initial Director's Interest Notice  
 
    APPOINTMENT OF CHIEF EXECUTIVE OFFICER AND NEW DIRECTOR  
 
    Change in Board Composition  
 
    Final Director's Interest Notice  
 
    Final Director's Interest Notice - IM  
 
    BIOXYNE Results of Meeting 20121129  
 
    AGM Presentation 29 November 2012 BXN  
 
    Extra Ordinary General Meeting To Set Future Direction  
 
    BioxyneCuts Costs To Focus On New Study  
 
    Bioxyne's Board Renewal  
 
    Initial Director's Interest Notice  
 
    Final Director's Interest Notice  
 
    Final Director's Interest Notice  
 
    Appendix 4C - quarterly  
 
    Results of Meeting  
 
    Notice of Annual General Meeting/Proxy Form  
 
    Final Director's Interest Notice  
 
    Director's Resignation  
 
    Shareholder Update  
 
    Amended Change of Director's Interest Notice  
 
    Change of Director's Interest Notice  
 
    Annual Report to shareholders  
 
    Bioxyne enters Heads of Agreement  
 
    Notice of General Meeting/Proxy Form  
 
    Preliminary Final Report  
 
    Notice of Requisition of Meeting from Wigram Trading Pty Ltd  
 
    Requisition of Meeting from Octa Philip Asset Management  
 
    Requisition of Shareholders Meeting  
 
    Appendix 4C - quarterly  
 
    Chairman's Address - slides  
 
    Investor Presentation  
 
    Update On Commercialisation Process  
 
    Chairman's Letter  
 
    Top 20 securityholders  
 
    Appendix 3B  
 
    Reinstatement to official quotation  
 
    Results of Phase 2b Study  
 
    Market Update On Suspension of Shares  
 
    Suspension from Official Quotation  
 
    Trading Halt  
 
    On Track To Report Clinical Trial Results In June  
 
    Appointment of Torreya Partners LLC  
 
    Initial Director's Interest Notice Jeremy L Curnock Cook  
 
    Investor Presentation  
 
    Quarterly Update and Appendix 4C  
 
    Becoming a substantial holder  
 
    Initial Director's Interest Notice  
 
    Becoming a substantial holder  
 
    Becoming a substantial holder  
 
    New Listed Drug Developer Bioxyne Postioned For Growth  
 
    Final Director's Interest Notice - Simon Taylor  
 
    Final Director's Interest Notice - Simon O'Loughlin  
 
    Initial Director's Interest Notice - William Harrison  
 
    Change of Director's Interest Notice - P Ford  
 
    Initial Director's Interest Notice - Glenn Crisp  
 
    Initial Director's Interest Notice - David Radford  
 
    Initial Director's Interest Notice - Ian Mutton  
 
    Becoming a substantial holder  
 
    New Australian Drug Developer Lists on ASX  
 
    Becoming a substantial holder  
 
    Share Trading Policy  
 
    Constitution of Company  
 
    Completion of Takeover of Hunter Immunology Limited  
 
    Pre-Quotation Disclosure  
 
    Becoming a substantial holder  
 
    Reinstatement to Official Quotation (04/04/12)  
 
    ASX Circular - Reinstatement to Official List  
 
    Change of Company Name to Bioxyne Limited  
 
    Appendix 3B  
 
    Top 20 securityholders  
 
    Range of Shares  
 
    Top 20 Option Holders  
 
    Completion of Takeover Offers and Compulsory Acquisition  
 
    Results of Meeting  
 
    Notification of Amended Timetable for Re-admission to ASX  
 
    Share Consolidation  
 
    Achievement of Minimum Subscription under Public Offer  
 
    Half Yearly Report and Accounts  
 
    Correction to Chairman's Address at General Meeting  
 
    Suspension from Official Quotation  
 
    Results of Meeting  
 
    Chairman's Address Delivered At The General Meeting  
 
    Trading Halt  
 
    Chairman's Address to Shareholders - Gen Meeting 7 Feb 2012  
 
    Extension Of Public Offer Period  
 
    First Supplementary Target's Statement By Hunter Immunology  
 
    Appendix 4C - quarterly  
 
    First Supplementary Bidder's Statement for Hunter Immunology  
 
    Replacement Prospectus  
 
    Notice of General Meeting/Proxy Form  
 
    Notice of Dispatch of Bidder's Statement  
 
    Replacement Prospectus  
 
    Appendix 3B Replacement Options  
 
    Target's Statement  
 
    Appendix 3B Public Offer  
 
    Bidder's Statement for Hunter Immunology Ltd  
 
    Prospectus to Raise a Maximum of $ 4,400,000  
 
    Issue Of Bidder's Statement in Connection with Takeover Bid  
 
    Section 708 A (6) Notice and Appendix 3B  
 
    Results of Meeting  
 
    Chairman's Address to Shareholders  
 
    Placement  
 
    Termination of Agreement with Nestec  
 
    Appendix 4C - quarterly  
 
    Notice of Annual General Meeting/Proxy Form  
 
    Reinstatement to Official Quotation  
 
    Proposed Merger Of Probiomics with Hunter Immunology  
 
    Suspension from Official Quotation  
 
    Trading Halt  
 
    Annual Report to shareholders  
 
    Preliminary Final Report  
 
    Appendix 4C - quarterly  
 
    PCC Response to ASX Query  
 
    Appendix 4C - quarterly  
 
    Half Yearly Report and Accounts  
 
    Appendix 4C - quarterly  
 
    Share Trading Policy  
 
    Results of Meeting  
 
    Chairman's Address to Shareholders  
 
    Registration of PCC in New Zealand for Companion Animals  
 
    Appendix 4C - quarterly  
 
    Repayment Of Convertible Notes  
 
    Annual Report to shareholders  
 
    Notice of Annual General Meeting/Proxy Form  
 
    Preliminary Final Report  
 
    Appendix 4C - quarterly  
 
    Press Release Chr Hansen to showcase PCC at Vitafoods Geneva  
 
    Chr. Hansen to introduce PCC at Vitafoods Geneva  
 
    Appendix 4C - quarterly  
 
    Half Yearly Report and Accounts  
 
    Appendix 4C - quarterly  
 
    Results of Meeting  
 
    Chairman's Address to Shareholders  
 
    CHR HANSEN PRESS RELEASE ON THE GLOBAL AGREEMENT  
 
    PROBIOMICS SIGNS AN EXCLUSIVE AGREEMENT WITH CHR. HANSEN  
 
    Trading Halt  
 
    Change of Director's Interest Notice  
 
    Appendix 4C - quarterly  
 
    Notice of Annual General Meeting/Proxy Form  
 
    Change of Director's Interest Notice  
 
    Change of Director's Interest Notice - Simon O'Loughlin  
 
    Change of Director's Interest Notice - Simon Taylor  
 
    Annual Report For The Year Ended 30 June 2009  
 
    PCC Effective In Reducing Illness in Athletes  
 
    Preliminary Final Report  
 
    Extension of Convertible Notes  
 
    Resignation of CEO  
 
    Quarterly Cashflow Report  
 
    Section 708A(6) Notice and Appendix 3B  
 
    Change of Director's Interest Notice  
 
    Results of Meeting  
 
    Private Placement  
 
    PCC Shown To Be Effective In Boosting Flu Vaccine In Trial  
 
    Appendix 4C - quarterly  
 
    Notice of General Meeting/Proxy Form  
 
    Half Yearly Report and Accounts  
 
    Appendix 4C - quarterly  
 
    Appendix 3B  
 
    Expiry of Unlisted Options  
 
    Change Of Director's Interest - S O'Loughlin  
 
    Change Of Director's Interest - S Taylor  
 
    Change Of Director's Interest - P Ford  
 
    Appendix 3B  
 
    Results of Meeting  
 
    Chairman's Address to Shareholders  
 
    Appendix 4C - quarterly  
 
    Notice of Annual General Meeting/Proxy Form  
 
    Annual Report 2008  
 
    Expiry of Unquoted Options and Extention of Con Notes  
 
    Response to ASX Query  
 
    Preliminary Final Report  
 
    Appendix 3B  
 
    Class Order Relief  
 
    Resignation Of Directors  
 
    Final Director's Interest Notice  
 
    Final Director's Interest Notice  
 
    Final Director's Interest Notice  
 
    Initial Director's Interest Notice  
 
    Initial Director's Interest Notice  
 
    Initial Director's Interest Notice  
 
    Market Update and Board Changes  
 
    Quarterly Cashflow Report  
 
    Change of Director's Interest Notice  
 
    Appendix 3B  
 
    Results of Meeting  
 
    Change of Registered Office Address  
 
    Chairman's Address to Shareholders  
 
    Notice of Annual General Meeting/Proxy Form  
 
    Commitments Test Entity - Third Quarter Report  
 
    Extension of Share Purchase Plan  
 
    Extension of Share Purchase Plan Offer  
 
    Market Update - Acquisition of Minomic International Limited  
 
    Market Update  
 
    Newsletter  
 
    Share Purchase Plan Offer Booklet and Application Form  
 
    Conditional acquisition of Minomic International Limited  
 
    Appointment of New Chief Executive Officer  
 
    Reinstatement to Official Quotation  
 
    Half Year Accounts  
 
    4 D - Half Yearly Report  
 
    Capital Raising Update  
 
    Commitments Test Entity - Second Quarter Report  
 
    Appendix 3B  
 
    Commitments Test Entity - First Quarter Report  
 
    Executes Global Finance Agreement with Nestle  
 
    Issue of Convertible Notes  
 
    Annual Report to shareholders  
 
    Preliminary Final Report  
 
    Commitments Test Entity - Fourth Quarter Report  
 
    Company Secretary Appointment  
 
    Issue of Unlisted Options  
 
    Lapse of Unlisted Options  
 
    Class order relief for share placement  
 
    Commitments Test Entity - Third Quarter Report  
 
    Appendix 3B  
 
    Share Placement  
 
    Lapse of unlisted employee options  
 
    Half Yearly Report & Accounts  
 
    Commitments Test Entity - Second Quarter Report  
 
    Issue of employee options  
 
    Results of AGM  
 
    Commitments Test Entity - First Quarter Report  
 
    Notice of Annual General Meeting  
 
    Lapse of Unlisted Options  
 
    2006 Annual Report  
 
    Ceasing to be a substantial holder  
 
    Issue of Options  
 
    Results of General Meeting  
 
    Preliminary Final Report  
 
    Notice of General Meeting  
 
    Class Order Relief for Placement of Shares  
 
    Appendix 3B  
 
    Commitments Test Entity - Fourth Quarter Report  
 
    Lapse of Options  
 
    Issue of employee share options  
 
    Commitments Test Entity - Third Quarter Report  
 
    Quarterly Newsletter  
 
    Half Yearly Report & Half Year Accounts  
 
    Lapse of listed options  
 
    Re-negotiates distribution contract  
 
    Commitments Test Entity - Second Quarter Report  
 
    Issue of options to Directors  
 
    Change of Director's Interest Notice  
 
    Clarification of media report on clinical trial  
 
    Appendix 3B  
 
    Lapse of employee share options  
 
    Results of AGM  
 
    Chairman's AGM Address to Shareholders  
 
    Extension of closing date of SPP  
 
    Flu vaccine clinical trial  
 
    Wins AJP Award  
 
    Receipt of Commercial Ready grant  
 
    Commitments Test Entity - First Quarter Report  
 
    Share Purchase Plan - Letter to Shareholders  
 
    Notice of Annual General Meeting  
 
    2005 Annual Report  
 
    Becoming a substantial holder  
 
    Becoming a substantial holder  
 
    Preliminary Final Report  
 
    Class order relief statement  
 
    Appendix 3B - Share Placement  
 
    Commitments Test Entity - Fourth Quarter Report  
 
    $1m Private Placement  
 
    Quarterly Newsletter to Shareholders  
 
    Final Director's Interest Notice  
 
    Appendix 3B - Issue of unlisted employee share options  
 
    Final Director's Interest Notice  
 
    Initial Director's Interest Notice  
 
    Board Changes & AIM Listing  
 
    Placement - ASIC Class Order Relief  
 
    Appendix 3B - Additional Working Capital  
 
    Amendment to previous announcement re Placement  
 
    Change of Trading Code to PCC  
 
    Fully Underwritten $1.0 million Placement & SPP  
 
    Commitments Test Entity - Third Quarter Report  
 
    Lapse of Employee Options  
 
    Appendix 3B - Issue of Employee Share Options  
 
    Results of General Meeting  
 
    Investor Presentation  
 
    Response to ASX Query  
 
    Product Launch boosted as FDA clamps down on competitors  
 
    Successful Completion-1st Stage Molecule Discovery Program  
 
    Initial Director's Interest Notice  
 
    Notice of General Meeting  
 
    Initial Director's Interest Notice  
 
    Initial Director's Interest Notice  
 
    Final Director's Interest Notice  
 
    Final Director's Interest Notice  
 
    Half Yearly Report & Half Year Accounts  
 
    Second Functional Food Agreement  
 
    Ceasing to be a substantial holder  
 
    Board Changes for AIM admission  
 
    Partners with Sanitarium  
 
    Trial to reduce ear infections in Aboriginal children  
 
    Becoming a substantial holder  
 
    Becoming a substantial holder  
 
    Commitments Test Entity - Second Quarter Report  
 
    VRI to List on AIM  
 
    Licensing Agreement with Largest Distributor in Asia  
 
    Form 484 - Selective reduction of capital  
 
    Appendix 3B - issue of options to a director  
 
    Final Director's Interest Notice  
 
    Results of AGM  
 
    Presentation to Investors  
 
    Commitments Test Entity - First Quarter Report  
 
    Notice of AGM & Special Meeting  
 
    Annual Report 2004  
 
    Annual Report  
 
    Rowett Research Institute project  
 
    Preliminary Final Report  
 
    Significant interest in Atopic Dermatitis Trial Results  
 
    Lapse of Options  
 
    App 3B -Part consideration for arranging placement of shares  
 
    Commitments Test Entity - Fourth Quarter Report  
 
    Appendix 3B - New issue  
 
    Disclosure Document  
 
    Amended Appendix 3B - For additional funding of operations  
 
    Placement - ASIC Class Order Relief  
 
    Appendix 3B - For additional funding of company's operations  
 
    successful Phase II Trial Results for Atopic Dermatitis  
 
    Results of Meeting  
 
    Ceasing to be a substantial holder  
 
    Death of Mr Jim Grant -Chairman  
 
    Change in substantial holding  
 
    Issue of Bonus Options to Shareholders  
 
    Chairman's Letter to Shareholders/Notice of General Meeting  
 
    Placement  
 
    Launches new proTract range of Probiotics  
 
    Registration of Progastrim in Singapore  
 
    Appointment of Medical & Scientific Advisory Board  
 
    Commitments Test Entity - Third Quarter Report  
 
    Appendix 3B - Fund companys operations  
 
    Placement & Forthcoming Rights Issue raising $2.9m  
 
    Advances Plans for Product Distribution in Asia & US  
 
    Shareholder Update from Managing Director  
 
    Half Yearly Report & Half Year Accounts  
 
    Response to ASX Appendix 4C Query  
 
    Commitments Test Entity - Second Quarter Report  
 
    Ceasing to be a substantial holder  
 


Supplier Member

Bioxyne Ltd.

Suite 506, Level 5
50 Clarence St
Sydney, NSW 2000, Australia

P: +61 2 9078 8180
E: info@bioxyne.com
ABN: 97 084 464 193

Home

Sign Up